Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
COMMENTARY
With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
To read the full story
Related Article
- Chuikyo OKs Plan for September Drug Price Survey, Smaller Coverage amid COVID-19
July 22, 2020
- 2020 Policy Blueprint Restresses Efforts on COVID-19 Meds/Vaccines; Drug Price Survey Up for Discussion on July 22
July 20, 2020
- Japan Govt Adopts 2020 Honebuto Policy, Drug Price Survey to Be Conducted This Autumn
July 17, 2020
- Japan Govt to Push Ahead with Off-Year Survey, Considering COVID-19 Impact to Decide on Re-Pricing
July 16, 2020
- Japan Govt to Tweak Honebuto Text for Off-Year Re-Pricing, but Still Holds to Original Plan
July 15, 2020
- LDP Lawmakers Irked as Govt Stands Fast on Off-Year Re-Pricing/Survey Plan; Honebuto Text Tweak Unclear
July 10, 2020
- Original Plan Remains Unchanged for Off-Year Drug Re-Pricing, Survey: Minister
July 9, 2020
- Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
- Japan Govt Likely to Stick to 2020 Off-Year Drug Re-Pricing Plan in Honebuto Paper
July 6, 2020
- Ruling Parties Call for Careful Discussions on Off-Year Drug Re-Pricing
July 3, 2020
- LDP’s Coronavirus Task Force Calls for Caution in Off-Year Re-Pricing Debate
June 26, 2020
- LDP Pharma Study Group Submits Proposal, Says Off-Year Re-Pricing Should Be Delayed
June 19, 2020
COMMENTARY
- Revision of Guidelines on Drone Drug Deliveries Expected by March-End: Will Powerful Meds Be OK'ed?
March 17, 2023
- FY2024 Pricing Reform Likely to Focus on “Balance” between Rewarding Innovation and Optimizing LLP Prices
February 6, 2023
- LDP Expects to Finalize Tax Reform Plan This Week; Will It Expand R&D Credit System?
December 13, 2022
- Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
- Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
November 22, 2022
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…